Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday

Krystal Biotech (NASDAQ:KRYS) is projected to announce its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $1.62 per share and revenue of $105.30 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 8:30 AM ET.

Krystal Biotech Stock Up 2.3%

Shares of NASDAQ KRYS opened at $276.45 on Monday. The company has a market capitalization of $8.02 billion, a PE ratio of 41.45 and a beta of 0.49. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $295.98. The firm has a fifty day simple moving average of $262.06 and a 200 day simple moving average of $206.09.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the transaction, the chief accounting officer directly owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 13.70% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in KRYS. FORA Capital LLC bought a new position in shares of Krystal Biotech during the 4th quarter worth approximately $521,000. Marshall Wace LLP increased its position in shares of Krystal Biotech by 42.5% during the fourth quarter. Marshall Wace LLP now owns 183,754 shares of the company’s stock valued at $45,303,000 after acquiring an additional 54,794 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Krystal Biotech by 17.9% during the fourth quarter. The Manufacturers Life Insurance Company now owns 40,629 shares of the company’s stock worth $10,056,000 after acquiring an additional 6,174 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in Krystal Biotech by 3.2% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 22,087 shares of the company’s stock worth $5,446,000 after acquiring an additional 689 shares during the period. Finally, Bridgewater Associates LP boosted its position in Krystal Biotech by 3.0% in the fourth quarter. Bridgewater Associates LP now owns 10,015 shares of the company’s stock worth $2,469,000 after purchasing an additional 292 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on KRYS. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. The Goldman Sachs Group lifted their target price on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Citigroup raised their price objective on shares of Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $277.89.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.